Pertinax Pharma are delighted to announce that Simon Hubbert has joined the Board of Directors as Non- Executive Chairman. Simon has over 25 years’ experience in the medical device industry and has held CEO, senior commercial and general management position in both public and private global medtech
Team Pertinax were very proud to visit our PhD student Matthew Skeats at the University of Bristol's fantastic Research Without Borders public engagement event yesterday. Matt, who is also supported by the Industrial Challenge Strategy Fund, presented an engaging and thought-provoking stand on the
We are delighted to have received notification that our EU patent has been granted. Our substance of matter patent protects Pertinax materials without reference to particular applications, and as such forms the strongest patent protection possible for materials of this nature.
We are excited to be in the running for a prize! The Great West Awards celebrate the best science and technology start-ups in the UK's South West and Wales.
Our fabulous Senior Development Scientist Alex was interviewed recently about life at Pertinax. Find out what she had to say about our activities, challenges and aspirations here!
To read our case study, click here!
Pertinax Pharma are delighted to announce that they have secured funding from Innovation 4 Growth (I4G). I4G is a funding scheme managed by the University of the West of England and developed using the European Regional Development Fund. It supports SMEs in the West of England to develop innovative
Pertinax Pharma Ltd is delighted to announce the successful closing of its latest £860,000 funding round. The investment was provided by national investors Mercia Fund Managers and Perivoli Innovations, both following on, and new investor Syndicate Room. Peter Dines, Chief Operating Officer at